ADVANCING THE FIRST ACCOMMODATING
INTRAOCULAR LENS
INTRAOCULAR LENS
(AIOL)THAT REPLICATES NATURAL VISION
TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0

THE OPPORTUNITY
THE OPPORTUNITY
Breakthrough Innovation

- Successful First-In-Human (FIH) implants – August 2025
- Designed for rapid, dynamic focus – near to far in <1 second
- Multiple global patents & patents pending
Strong Leadership

- CEO Dean Burns: ex-Alcon Vision ($750M BU, 15 FDA approvals, $6B in product launches)
- Backed by 12 leading ophthalmology advisors
Massive Market Opportunity

- $4.5B+ global IOL market, growing 3–5% CAGR
- Initial focus: $1.2B premium cataract segment (65+)
- Expansion pipeline into larger adjacent markets
Industry Validation

- 4 of top 7 global eyecare companies requested FIH results
- Active M&A interest in next-gen vision correction technologies
Clear Roadmap To Commercialization (1)

- 30-patient First-in-Human study (2025–26)
- FDA multi-phase study (2026–28)
- CE Mark & early EU commercialization (2027)
(1) Timeline estimates are subject to change
THE PROBLEM – SIGHT LOSS WITH AGE
THE PROBLEM – SIGHT LOSS WITH AGE
THE PROBLEM – SIGHT LOSS WITH AGE

The eye deteriorates as we age developing the following conditions:
Existing solutions:
* (1) https://eyesoneyecare.com * (2) https://www.presbyopiaphysician.com

THE SOLUTION – OCUMETICS LENS
THE PROBLEM – SIGHT LOSS WITH AGE
THE PROBLEM – SIGHT LOSS WITH AGE

OCUMETICS LENS OVERVIEW
$4.5 BILLION
MANAGEMENT & DIRECTORS
MANAGEMENT & DIRECTORS
MANAGEMENT & DIRECTORS
TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0

Dean Burns
CEO, President & Director
Former Senior Director at Alcon Vision, managing a $750M business unit across devices, disposables, intraocular lenses (IOLs), and pharmaceuticals. Successfully led 15 FDA approvals and 15 product launches with a combined $6B commercial value, while partnering with 12 of the leading global advisors in Ophthalmology.

Roger Jewett CA, CPA
CFO & Director
With over 25 years of experience leading public and private companies, he has guided organizations through financings, M&A, and growth, closing more than $70 million in financings and completing over 40 acquisitions and divestitures. His track record includes turning around companies such as Enerjet and RCR, scaling startups like Rare Method and Jump On Flyaways, and cofounding Quantum Blockchain Technologies, which later merged with Ocumetics.

Dr. Garth Webb
FOUNDER, CSO & Director
He is the Founder of Ocumetics and sole inventor of the Bionic Lens™ technology platform, bringing over 45 years of experience in clinical eye care, vision science, and refractive technology innovation. A proven entrepreneur, he co-founded one of Canada’s largest optometry clinics and launched multiple health science ventures. As a leader in advancing medical optics, his mission is to transform vision and enhance quality of life.

Dr. Doyle Stulting
CHIEF MEDICAL OFFICER & DIRECTOR
He is a renowned corneal surgeon and recognized global leader in cataract, refractive surgery, and transplantation. He has served as Principal Investigator in multiple FDA clinical trials, including groundbreaking studies in corneal cross-linking, and is a former Chair of the FDA Ophthalmic Devices Panel and Past President of the American Society for Cataract and Refractive Surgery.

Dr. James B McRoberts,O.D.
Director
With over 40 years of experience in optometry, including private practice in British Columbia, he has served as Past President of the BC Association of Optometrists and as Registrar of the BC College of Optometrists. His career includes leadership roles across professional boards, regulatory bodies, and laser vision centers, along with contributions as a published author and lecturer on optometry practice and policy.

Michael Edwards
Director
He is a Director at Pinnacle Wealth Brokers, one of Canada’s largest Exempt Market Dealers, and President of Customized Insurance & Tax Solutions, specializing in insurance and investment products. A Chartered Life Underwriter with extensive expertise in tax, finance, and estate planning, he brings a strong foundation of technical knowledge and practical experience. His board involvement spans private companies, industry associations such as the PCMA, and several major charitable organizations.

Robert Quinn
Director
He is an independent businessman with extensive board, management, and legal experience in the international mining industry. Skilled in corporate governance, environmental oversight, M&A, financing, contracts, compliance, and litigation, he has a proven track record supporting companies in mine development and global exploration programs. He holds a Juris Doctor degree from the University of Denver School of Law and a Bachelor’s in Business Administration from the University of Denver.
TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0
NEWS RELEASES
NEWS RELEASES
LATEST NEWS
Calgary, AB – TheNewswire – January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the first tranche of its previously announced best efforts brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately
Calgary, AB – TheNewswire – December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November 25, 2025) brokered private placement (the “Offering”) on a best-efforts basis led by Centurion One Capital Corp. (the “Lead Agent”), the Corporation has amended the
Calgary, Alberta – TheNewswire – December 9, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to
















